Scientists are embarking on a new frontier in medicinal treatment. The successful use of controlled psychedelic products is becoming widely accepted by universities, government and research institutes and health care organizations to treat a variety of mental health issues, including anxiety and depression.
In the last decade, breakthrough findings have been published about the usefulness and application of psychedelic compounds like psilocybin, more commonly referred to as magic mushrooms. Psilocybin is a naturally occurring psychedelic prodrug compound, which is produced by more than 200 species of mushrooms.
After obtaining U.S. regulatory approval to research psychedelics in healthy volunteers, Johns Hopkins published a landmark study in 2006 about the safety and enduring positive effects of a single dose of psilocybin that triggered a renewed interest in psychedelic research around the world.
Since then, Johns Hopkins has published other groundbreaking studies in more than 60 respected scientific journals. The research demonstrates therapeutic effects in people experiencing addiction (alcohol, smoking, other drugs of abuse), existential distress caused by life-threatening disease, and treatment-resistant depression.
These studies have advanced the understanding of the enduring positive effects of psilocybin.
According to Paul B. Rothman, M.D., Dean of the Johns Hopkins University School of Medicine and CEO of Johns Hopkins Medicine, “Our scientists have shown that psychedelics have real potential as medicine.”
At the Johns Hopkins Center for Psychedelic and Consciousness Research, researchers focus on how psychedelics affect mood, behavior, cognition, brain function, and biological markers of health. Upcoming studies will determine the effectiveness of psilocybin as a new therapy for Alzheimer’s disease, opioid addiction, post-traumatic stress disorder (“PTSD”), anorexia nervosa, post-treatment Lyme disease syndrome (formerly known as chronic Lyme disease), and alcohol use in people with major depression.
The psychedelic market is only in the infancy stage. The psychedelic and functioning mushroom industries are among the fastest growing in North America. The global medicinal mushroom market is projected to reach $13.88 billion by 2024.
Proof is becoming increasingly available that the market is positioned for widespread acceptance. In March 2019, the FDA approved the first psychedelic medicinal product from Johnson & Johnson to treat depression, called Spravato. Later that year, in November 2019, the FDA awarded Breakthrough Therapy designation to non-profit Usona Institute, which is also studying the effects of psilocybin as an anti-depressant. In 2020, the FDA granted psychedelics Breakthrough Therapy status for treatment-resistant depression, with approvals anticipated in 2021.
As the industry transitions from dry biomass to extracts, few companies are prepared for this new opportunity. One such entity is Pure Extracts, an innovative extraction company focused on extracting the most valuable molecules from the psychedelic products. The margins associated with this part of the business are high. According to Doug Benville, founder and COO of Pure Extracts, “Even though people have been utilizing the therapeutic benefits of mushrooms for centuries, it is really only now starting to become a trend that Main Street and Wall Street are recognizing.”
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.PsychedelicNewsWire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
Editor@PsychedelicWire.com
PsychedelicNewsWire is part of the InvestorBrandNetwork.